Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDH1R132H dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- German Cancer Research Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The IDH1R132H dendritic cell vaccine is a personalized neoantigen-targeting therapeutic vaccine designed to treat IDH1-mutant gliomas. It functions by utilizing autologous dendritic cells, which are isolated from the patient and then loaded ex-vivo with a specific peptide derived from the isocitrate dehydrogenase 1 (IDH1) R132H neoantigen. Upon re-administration, these antigen-presenting dendritic cells stimulate the patient's immune system, particularly CD4+ and CD8+ T cells, to recognize and mount an immune response against tumor cells expressing the mutant IDH1 protein. This approach aims to specifically target and eliminate cancer cells while minimizing off-target toxicity. The German Cancer Research Center (DKFZ) and the University Hospital Heidelberg have been key in its development and early clinical trials.
- Other names
- IDH1 R132H peptide vaccinationIDH-1 R132H peptide vaccinationIDH 1 R132H peptide vaccinationIDH1R132H-DC vaccineIDH-1R132H-DC vaccineIDH 1R132H-DC vaccine
02
Targets
IDH1 R132H (Isocitrate Dehydrogenase 1 R132H)
Beyond the preview
Go deeper on IDH1R132H dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDH1R132H dendritic cell vaccine.